BioWorld - Wednesday, January 28, 2026

BioWorld Science

Aug. 5, 2021

View Archived Issues

Qurient initiates phase II study of telacebec in moderate COVID-19

Read More

Enrollment opens in phase I study of LP-168 in relapsed or refractory B-cell malignancies

Read More

RGS10 gene mutations linked to combined immunodeficiency

Read More

Allergy Therapeutics reports findings from ex vivo biomarker study of VLP Peanut

Read More

FDA clears IND for [225Ac]PSMA I&T for mCRPC

Read More

PanTher receives ethics approval to initiate phase I study of PTM-101 in Australia

Read More

Merck & Co. identifies new arginase inhibitors

Read More

New MAP2K inhibitors discovered at Immuneering Corp.

Read More

GB-5001 demonstrates safety in toxicity study in dogs

Read More

The University of Washington and the Department of Veterans Affairs patent glycolysis inhibitors

Read More

New cyclophilin ligands described by Harvard College

Read More

Exosomes conjugated to VEGF antibodies show efficacy in models of choroidal neovascularization

Read More

Target engagement, safety seen with anti-TREM-2 monoclonal antibody AL-002 in healthy subjects

Read More

GWAS gives clues to menopause, and healthy aging

Read More

89Zr-Immuno-PET using bispecific Abeta MAb as promising diagnostic strategy for Alzheimer's disease

Read More

Updated results provided for ACI-24 in adults with Down syndrome

Read More

Telix initiates first-in-human study of next-generation prostate cancer therapy candidate TLX-592

Read More

Noema studies PDE10A inhibitor NOE-105 for Tourette's syndrome in phase IIa

Read More

KIR3DL3-HHLA2 pathway could be targeted for cancer immunotherapy

Read More